Cannabis Use in First-Episode Psychosis: Associations with Symptom Dimensions and Sociodemographic Factors

Aziz Mohammad

doi:10.63050/jpps.23.01.1178

Aziz Mohammad Khyber Medical College Peshawar

DOI: https://doi.org/10.63050/jpps.23.01.1178

Keywords: First Episode Psychosis, Cannabis Use, Acute Psychosis, PANSS

Abstract

Abstract

Objective:
To determine sociodemographic and clinical predictors of cannabis use among patients with first-episode psychosis (FEP) admitted to a tertiary care psychiatric unit in Pakistan.

Methods:
This cross-sectional study was conducted at the Psychiatry Unit, Khyber Teaching Hospital, Peshawar, from January 2021 to December 2024. Consecutive inpatients with FEP and no prior antipsychotic exposure were assessed using a structured proforma for sociodemographic and clinical data. Symptom severity was measured with the Positive and Negative Syndrome Scale (PANSS). Binary logistic regression was applied to identify predictors of cannabis use.

Results:
Among 104 participants (77.9% male; mean age 23.4 ± 8.4 years), cannabis use was reported exclusively among males (28.4%). Unemployment and lower socioeconomic status significantly predicted cannabis use. Being employed (OR = 0.017, 95% CI [0.001–0.367]) or a student (OR = 0.064, 95% CI [0.006–0.693]) was associated with markedly lower odds of cannabis use compared with unemployment. Satisfactory socioeconomic status was also protective (OR = 0.074, 95% CI [0.010–0.522]). Clinically, moderate manic symptoms and higher PANSS activation scores were linked with lower likelihood of cannabis use (p < 0.05).

Conclusion:
Cannabis use in first-episode psychosis is strongly influenced by social determinants such as occupation and socioeconomic status rather than symptom severity. Culturally informed, gender-sensitive prevention strategies are needed to address substance use risk in psychosis within South Asian contexts.

Downloads

Download data is not yet available.

References

1. Larsen T, Melle I, Auestad B, Friis S, Haahr U, Johannessen J, et al. Substance abuse in first-episode non-affective psychosis. Schizophr Res. 2007;88(1-3):55–62.
2. Addington J, Case N, Saleem MM, Auther AM, Cornblatt BA, Cadenhead KS. Substance use in clinical high risk for psychosis: a review of the literature. Early Interv Psychiatry. 2014;8(2):104–12.
3. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262–9.
4. Martin MJ, Conger RD, Sitnick SL, Masarik AS, Forbes EE, Shaw DS. Reducing risk for substance use by economically disadvantaged young men: positive family environments and pathways to educational attainment. Child Dev. 2015;86(6):1719–37.
5. Stephens JR, Heffner JL, Adler CM, Blom TJ, Anthenelli RM, Fleck DE, et al. Risk and protective factors associated with substance use disorders in adolescents with first-episode mania. J Am Acad Child Adolesc Psychiatry. 2014;53(7):771–9.
6. Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 2010;36(6):1115–30.
7. Saquib N, Rajab AM, Saquib J, AlMazrou A. Substance use disorders in Saudi Arabia: a scoping review. Subst Abuse Treat Prev Policy. 2020;15(1):41.
8. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005;187:510–5.
9. Ringen PA, Nesvåg R, Helle S, Lagerberg TV, Lange EH, Løberg EM, et al. Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder. Psychol Med. 2016;46(15):3127–36.
10. Kay SR, Opler LA, Lindenmayer J-P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989;155(S7):59–65. https://doi.org/10.1192/S0007125000291514
11. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res. 1988;23(1):99–110.
12. Kalsoom U, Mukhtar-ul-Haq Azeemi M, Farid K. Substance use among students of professional institutes of Khyber Pakhtunkhwa. J Postgrad Med Inst. 2014;28(1):34–8.
13. Mousavi SB, Higgs P, Piri N, Sadri E, Pourghasem M, Jafarzadeh Fakhari S, et al. Prevalence of substance use among psychotic patients and determining its strongest predictor. Iran J Psychiatry. 2021;16(2):124–30.
14. Reininghaus UA, Morgan C, Simpson J, Dazzan P, Morgan K, Doody GA, et al. Unemployment, social isolation, achievement-expectation mismatch and psychosis: findings from the AESOP Study. Soc Psychiatry Psychiatr Epidemiol. 2008;43(9):743–51.
15. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry. 2007;190:515–20.
16. Compton MT, Weiss PS, West JC, Kaslow NJ. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol. 2005;40(12):939–46.
17. Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, et al. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2014;44(3):499–506.
18. El Hayek S, Lasebikan V, Noroozi A. Editorial: Alcohol and drug use in low- and middle-income countries. Front Psychiatry. 2024;15:1381726.
19. Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15(3):195–204.